Ian R. Outhwaite

Ian R. Outhwaite

Auto-generated profile, based on publicly available information

Ian R. Outhwaite

Department of Pharmacological Sciences, Stony Brook University, Stony Brook, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in eLife
Verified
Journal Article
Open access
XHXiaowei Hou
Xiaowei Hou
IOIan R Outhwaite
Ian R Outhwaite
LPLeanne Pedi
Leanne Pedi
SLStephen Barstow Long
Stephen Barstow Long
The calcium release-activated calcium channel Orai regulates Ca2+ entry into non-excitable cells and is required for proper immune function. While the channel typically opens following Ca2+ release from the endoplasmic reticulum, certain pathologic mutations render the channel constitutively open. Previously, using one such mutation (H206A), we obtained low (6.7 Å) resolution X-ray structural information on Drosophila melanogaster Orai in an open conformation (Hou et al., 2018). Here we present a structure of this open conformation at 3.3 Å resolution using fiducial-assisted cryo-electron microscopy. The improved structure reveals the conformations of amino acids in the open pore, which dilates by outward movements of subunits. A ring of phenylalanine residues repositions to expose previously shielded glycine residues to the pore without significant rotational movement of the associated helices. Together with other hydrophobic amino acids, the phenylalanines act as the channel’s gate. Structured M1–M2 turrets, not evident previously, form the channel’s extracellular entrance.

16 February 2023 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
VMVictoria R. Mingione
Victoria R. Mingione
YPYiTing Paung
YiTing Paung
IOIan R. Outhwaite
Ian R. Outhwaite
MSMarkus August Seeliger
Markus August Seeliger
The human genome encodes more than 500 different protein kinases: signaling enzymes with tightly regulated activity. Enzymatic activity within the conserved kinase domain is influenced by numerous regulatory inputs including the binding of regulatory domains, substrates, and the effect of post-translational modifications such as autophosphorylation. Integration of these diverse inputs occurs via allosteric sites that relate signals via networks of amino acid residues to the active site and ensures controlled phosphorylation of kinase substrates. Here, we review mechanisms of allosteric regulation of protein kinases and recent advances in the field.

26 September 2022 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
APAlexander A. Peterson
Alexander A. Peterson
ARAziz M. Rangwala
Aziz M. Rangwala
MTManish K. Thakur
Manish K. Thakur
PWPatrick S. Ward
Patrick S. Ward
CHChristie Hung
Christie Hung
DLDavid R. Liu
David R. Liu
Although cyclophilins are attractive targets for probing biology and therapeutic intervention, no subtype-selective cyclophilin inhibitors have been described. We discovered novel cyclophilin inhibitors from the in vitro selection of a DNA-templated library of 256,000 drug-like macrocycles for cyclophilin D (CypD) affinity. Iterated macrocycle engineering guided by ten X-ray co-crystal structures yielded potent and selective inhibitors (half maximal inhibitory concentration (IC50) = 10 nM) that bind the active site of CypD and also make novel interactions with non-conserved residues in the S2 pocket, an adjacent exo-site. The resulting macrocycles inhibit CypD activity with 21- to >10,000-fold selectivity over other cyclophilins and inhibit mitochondrial permeability transition pore opening in isolated mitochondria. We further exploited S2 pocket interactions to develop the first cyclophilin E (CypE)-selective inhibitor, which forms a reversible covalent bond with a CypE S2 pocket lysine, and exhibits 30- to >4,000-fold selectivity over other cyclophilins. These findings reveal a strategy to generate isoform-selective small-molecule cyclophilin modulators, advancing their suitability as targets for biological investigation and therapeutic development.

31 July 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
ALAriel Leyte-Vidal
Ariel Leyte-Vidal
RDRosaAnna DeFilippis
RosaAnna DeFilippis
IOIan R. Outhwaite
Ian R. Outhwaite
IKIsabelle Kwan
Isabelle Kwan
JLJi Young Lee
Ji Young Lee
NSNeil P. Shah
Neil P. Shah

19 September 2022 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
HPHannah E. Phillips
Hannah E. Phillips
RJRebecca B. Jennings
Rebecca B. Jennings
IOIan R. Outhwaite
Ian R. Outhwaite
SGSarah Grosser
Sarah Grosser
MCMansi Chandra
Mansi Chandra
SPStephen G. Post
Stephen G. Post

4 December 2023 in eLife
Verified
Journal Article
Open access
IOIan R Outhwaite
Ian R Outhwaite
SSSukrit Singh
Sukrit Singh
BBBenedict-Tilman Berger
Benedict-Tilman Berger
SKStefan Knapp
Stefan Knapp
JCJohn Chodera
John Chodera
MSMarkus August Seeliger
Markus August Seeliger
Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the development of selective kinase inhibitors. Inhibition of off-target kinases makes it difficult to study the mechanism of inhibitors in biological systems. Current efforts focus on the development of inhibitors with improved selectivity. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target effects. We develop a multicompound–multitarget scoring (MMS) method that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables optimization of inhibitor combinations for multiple on-targets. Using MMS with published kinase inhibitor datasets we determine potent inhibitor combinations for target kinases with better selectivity than the most selective single inhibitor and validate the predicted effect and selectivity of inhibitor combinations using in vitro and in cellulo techniques. MMS greatly enhances selectivity in rational multitargeting applications. The MMS framework is generalizable to other non-kinase biological targets where compound selectivity is a challenge and diverse compound libraries are available.